Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
NCT07275060Phase 4Active, not recruiting
- Sponsor
- Canadian Immunization Research Network
- Start
- Oct 2025
- Primary completion
- Feb 2027
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) in Avian influenza A H5N1 (H5N1), sponsored by Canadian Immunization Research Network. Started Oct 2025; status: active, not recruiting.
02
Drugs
Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)
03
Conditions
Avian influenza A H5N1 (H5N1)
Beyond the preview
Go deeper on NCT07275060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07275060.